Filing Flows › Tela Bio (TELA) › Q2 2026 › vs Q2 2025
Tela Bio (TELA) Q2 2026 vs Q2 2025 (year over year)
Tela Bio's revenue fell $906K (-4%) from $20.2M in Q2 2025 to $19.3M in Q2 2026.
Tela Bio, Q2 2026: revenue $19.3M (-4% year over year), operating margin -48.1%, net loss $11.3M, operating cash flow −$9.4M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $19.3M | $20.2M | −$906K | -4% |
| Net loss | $11.3M | $9.9M | $1.3M | +13% |
| Costs & expenses | $30.6M | $30.1M | $433K | +1% |
| Operating costs | $28.6M | $29.3M | −$704K | -2% |
| Interest & other, net | $1.9M | $809K | $1.1M | +137% |
| Income tax | $60K | $33K | $27K | +82% |
| Cost of revenue | $5.3M | $6.1M | −$744K | -12% |
| Research & development | $2.7M | $2.2M | $520K | +24% |
| Sales & marketing | $16.4M | $16.9M | −$415K | -2% |
| General & admin | $4.1M | $4.1M | −$65K | -2% |
| Operating cash sources | $11.3M | $9.9M | $1.3M | +13% |
| Depreciation | $171K | $175K | −$4K | -2% |
| Share-based compensation | $613K | $985K | −$372K | -38% |
| Working capital & other | $1.1M | $858K | $239K | +28% |
| Cash used in operations | $9.4M | $7.9M | $1.5M | +19% |
| Net loss absorbed | $11.3M | $9.9M | $1.3M | +13% |
Questions
How much did Tela Bio's revenue grow year over year in Q2 2026?
Tela Bio's revenue fell $906K (-4%) from $20.2M in Q2 2025 to $19.3M in Q2 2026.